Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
PLX
#3115
Protalix BioTherapeutics, Inc. Common Stock
2.830
0
USD
+1.07%
Sektör:
Sağlık hizmetleri
Baz:
USD
Kar para birimi:
USD
Günlük aralık
Yıllık aralık
Günlük değişim
+1.07%
Aylık değişim
-3.08%
6 aylık değişim
-3.08%
Yıllık değişim
-3.08%
Önceki kapanış
2.800
0
Open
2.820
0
Bid
2.830
0
Ask
2.833
0
Low
2.789
0
High
2.845
0
Hacim
288
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
PLX
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
45.38 M
46.32 M
57.35 M
73.05 M
78.03 M
—
Valuation ratios
Enterprise value
146.47 M
-463.88 K
61.46 M
109.32 M
126.94 M
576.27 M
Price to earnings ratio
—
-1.34
-4.42
20.22
47
142.39
Price to sales ratio
—
0.96
1.39
2.29
2.85
10.78
Price to cash flow ratio
—
3.57
2.66
113.82
17.57
54.4
Price to book ratio
—
6.08
6.24
4.47
3.53
6.41
Enterprise value to EBITDA ratio
19.58
-0.02
2.25
2.7
-36.71
66.6
Profitability ratios
Return on assets %
0.1
0.37
0.27
0.1
0.04
0.01
Return on equity %
0.24
4.57
1.4
0.25
0.07
0.02
Return on invested capital %
—
—
251.84
146.84
30.81
10.67
Gross margin %
82.71
57.37
58.87
64.91
54.46
213.66
Operating margin %
4.31
53.36
27.32
15.97
7.34
24.99
EBITDA margin %
11.89
63.31
57.44
61.9
-6.48
1.05
Net margin %
10.37
71.92
31.33
12.69
5.49
18.09
Liquidity ratios
Quick ratio
0.49
1.32
0.87
1.12
1.52
7.1
Current ratio
0.64
1.86
1.38
1.54
2.34
10.58
Inventory turnover
0.03
0.03
0
0.04
0
—
Asset turnover
1.11
0.54
0.74
0.93
0.68
0.83
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.86
0.38
0.51
0.24
0
—
Long term debt to total equity ratio
2.16
4.62
2.65
0.6
0
—
Per share metrics
Operating cash flow per share
—
0.23
0.52
0.02
0.11
0.23
EBIT per share
—
0.46
0.54
0.47
-0.06
0.04
EBITDA per share
—
0.55
0.56
0.49
-0.04
0.06
Total debt per share
—
—
—
—
—
—
Cash per share
—
0.88
0.35
0.29
0.24
0.9
Net current asset value per share
—
1.4
0.93
0.85
0.74
3.22
Tangible book value per share
—
0.14
0.22
0.41
0.53
2.44
Working capital per share
—
0.65
0.26
0.3
0.43
2
Book value per share
—
0.14
0.22
0.41
0.53
2.44
Protalix BioTherapeutics Inc (DE)
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Haberler
Brazil judge overrules decisions suspending changes to meal voucher system
A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)
Pluxee ve Edenred hisseleri olumlu sonuçlar ve görünüm sonrası yükseldi
Pluxee, Edenred shares jump after upbeat results and outlook
Pluxee 2026 Mali Yılı 1. Çeyrek Sunumu: Brezilya Zorluklarına Rağmen %9 Gelir Artışı
Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds
Protalix, 2026 stratejisinde kontrolsüz gut tedavisine odaklanıyor
Tuesday’s Insider Activity: Key Execs Make Notable Trades
Protalix BioTherapeutics CEO’su Bashan Dror, 101 bin dolarlık hisse alımı gerçekleştirdi
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)
Protalix ve Secarna nadir böbrek hastalıkları tedavileri geliştirmek için ortaklık kurdu
Protalix and Secarna partner to develop rare kidney disease treatments